These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 15681532)

  • 1. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
    McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatofibrosarcoma protuberans: recent clinical progress.
    McArthur G
    Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Targeted therapy of dermatofibrosarcoma with imatinib].
    Ugurel S
    J Dtsch Dermatol Ges; 2007 Mar; 5(3):261. PubMed ID: 17338806
    [No Abstract]   [Full Text] [Related]  

  • 4. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
    Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
    Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications.
    Llombart B; Sanmartín O; López-Guerrero JA; Monteagudo C; Serra C; Requena C; Poveda A; Vistós JL; Almenar S; Llombart-Bosch A; Guillén C
    Histopathology; 2009 Jun; 54(7):860-72. PubMed ID: 19635106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
    Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C
    Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
    Han A; Chen EH; Niedt G; Sherman W; Ratner D
    Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results.
    Malhotra B; Schuetze SM
    Curr Opin Oncol; 2012 Jul; 24(4):419-24. PubMed ID: 22510939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
    Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
    Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
    Zhu JH; Li QW; Xiao WH; Sun JZ; Wang RL; Lu JY
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):470-2. PubMed ID: 21875491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
    Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
    Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
    Sjöblom T; Shimizu A; O'Brien KP; Pietras K; Dal Cin P; Buchdunger E; Dumanski JP; Ostman A; Heldin CH
    Cancer Res; 2001 Aug; 61(15):5778-83. PubMed ID: 11479215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
    Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
    Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior.
    McArthur GA
    Curr Opin Oncol; 2006 Jul; 18(4):341-6. PubMed ID: 16721128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
    Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
    Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New molecular approaches in dermatofibrosarcoma protuberans].
    Kaya G
    Rev Med Suisse; 2009 Jul; 5(211):1519-24. PubMed ID: 19694363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
    Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
    Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
    Rutkowski P; Van Glabbeke M; Rankin CJ; Ruka W; Rubin BP; Debiec-Rychter M; Lazar A; Gelderblom H; Sciot R; Lopez-Terrada D; Hohenberger P; van Oosterom AT; Schuetze SM; ;
    J Clin Oncol; 2010 Apr; 28(10):1772-9. PubMed ID: 20194851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
    Stacchiotti S; Pedeutour F; Negri T; Conca E; Marrari A; Palassini E; Collini P; Keslair F; Morosi C; Gronchi A; Pilotti S; Casali PG
    Int J Cancer; 2011 Oct; 129(7):1761-72. PubMed ID: 21128251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.
    Rutkowski P; Dębiec-Rychter M; Nowecki Z; Michej W; Symonides M; Ptaszynski K; Ruka W
    J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):264-70. PubMed ID: 20569296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.